Concourse Financial Group Securities, Inc. Chinook Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share
Q2 2023 Aug 10, 2023	BUY	$18.66 - $38.58 $0 - $0
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$18.63 - $27.35 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$17.51 - $23.37 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$12.59 - $18.8 $0 - $0
Q1 2022 May 09, 2022	BUY	$12.02 - $16.69 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$10.69 - $16.83 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$11.5 - $14.86 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$13.6 - $18.98 $0 - $0
Q1 2021 May 13, 2021	BUY	$14.17 - $19.11 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$11.9 - $20.91 $0 - $0

Others Institutions Holding KDNY

# of Institutions

Shares Held

234K

Call Options Held

Put Options Held

View Full List

About CHINOOK THERAPEUTICS, INC.

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

More about KDNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account